Illuccix (Gozetotide)

Gozetotide is designed to bind selectively to a cell‑surface receptor that plays a role in immune regulation. By engaging this receptor, the molecule modulates downstream signaling pathways, which may alter cytokine release and immune cell activation. The exact pharmacological mechanisms are still being clarified in early‑phase trials.

Dosing of Illuccix is determined by the prescribing clinician based on the specific clinical trial protocol or investigational use. The dose may vary according to the patient’s condition, body weight, and other therapeutic considerations, and should only be administered under professional medical supervision.

Safety data for gozetotide during pregnancy or lactation are insufficient. Because the drug is investigational, it is generally recommended to avoid use in pregnant or breastfeeding women unless the potential benefit justifies the potential risk and a specialist is consulted.

To request Illuccix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will ask for trade or institutional credentials. The team then provides pricing, availability, shipping details—including cold‑chain handling if needed—and assists with any required import documentation.

Illuccix is an investigational peptide with a mechanism distinct from approved monoclonal antibodies or small‑molecule immunomodulators. While other agents target similar immune pathways, direct comparative data are not yet available, and any assessment of relative efficacy or safety must await results from head‑to‑head clinical studies.

Illuccix should be stored refrigerated between 2 °C and 8 °C. Keep the vials in their original packaging, protect them from light, and do not freeze or agitate the solution. If temperature excursions occur, discard the product according to the supplier’s guidelines.

Illuccix is supplied as an intravenous solution and must be administered by a qualified healthcare professional. The infusion is typically performed in a clinical setting where the patient can be monitored for any immediate reactions, following the specific protocol outlined by the treating physician.

The most serious potential risks observed in early studies include severe hypersensitivity reactions such as anaphylaxis, cytokine release syndrome, and rare organ toxicity affecting the liver or kidneys. Patients receiving Illuccix should be closely monitored, and emergency measures must be readily available during infusion.

Illuccix should not be used in individuals with known hypersensitivity to gozetotide or any of its excipients, in patients with uncontrolled severe organ impairment, and in pregnant or breastfeeding women due to the lack of safety data. Use is also contraindicated when live vaccines are being administered concurrently.